Related Experiment Video
Updated: Jun 27, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Low-density lipoprotein cholesterol response to statins according to comorbidities and co-medications: A
Giulia Corn1, Marie Lund2, Niklas W Andersson3
1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.; Danish Cancer Institute, Statistics and Data Analysis, Copenhagen, Denmark.
Insights
Statin therapy response varies, but most conditions and medications have little effect. Metformin use significantly enhances LDL-C reduction, potentially allowing for lower statin doses in patients taking this drug.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Pharmacy
Background:
- Statin therapy effectiveness in lowering low-density lipoprotein cholesterol (LDL-C) shows significant individual variability.
- This variability may be influenced by co-morbidities and co-medications, impacting treatment strategies.
- Investigating these factors is crucial for optimizing statin therapy in diverse patient populations.
Purpose of the Study:
- To determine if common co-morbidities and co-medications significantly impact individual patient responses to statin therapy.
- To identify specific patient subgroups that may benefit from adjusted statin regimens based on their health status and concomitant drug use.
Main Methods:
- A Danish register-based cohort study of 89,006 patients initiating simvastatin or atorvastatin between 2008-2018.
- LDL-C reduction was calculated as percentage reduction difference (PRD) from pre-statin to on-statin levels.
- Linear regression analyzed PRD across 175 comorbidities and 99 co-medications, assessing statistical and clinical significance (PRD ≥ 5%).
Main Results:
- Concomitant use of oral blood-glucose lowering drugs, primarily metformin, was linked to a clinically significant and statistically important enhanced statin response (PRD 5.18%).
- No other comorbidity or co-medication met the criteria for a clinically important effect on statin response.
- Collectively, comorbidities and co-medications explained only 1.7% of the total population variance in statin response.
Conclusions:
- Most studied comorbidities and co-medications do not clinically impact statin response, suggesting general treatment regimens are appropriate.
- Metformin use is associated with significantly improved LDL-C response to statins.
- This finding suggests potential for using lower statin doses in patients concurrently treated with metformin.
Background:
The response of low-density lipoprotein cholesterol (LDL-C) to statin therapy is variable, and may be affected by the presence of co-morbid conditions or the use of concomitant medications. Systematic variation in the response to statins based on these factors could affect the selection of the statin treatment regimen in population subgroups. We investigated whether common comorbidities and co-medications had clinically important effects on statin responses in individual patients.
Methods:
This register-based cohort study included 89,006 simvastatin or atorvastatin initiators with measurements of pre-statin and on-statin LDL-C levels, in Denmark, 2008-2018. We defined statin response as the percentage reduction in LDL-C, and used linear regression to estimate percentage reduction differences (PRD) according to 175 chronic comorbidities and 99 co-medications. We evaluated both the statistical significance (P-values corrected for multiple testing) and the clinical importance (PRD of 5 percentage points or more) of the observed associations.
Results:
Concomitant use of oral blood-glucose lowering drugs, which included metformin in 96% of treated individuals, was associated with a greater response to statin therapy that was both statistically significant and clinically important, with a PRD of 5.18 (95% confidence interval: 4.79 to 5.57). No other comorbidity or co-medication reached the prespecified thresholds for a significant, clinically important effect on statin response. Overall, comorbidities and co-medications had little effect on statin response, and altogether explained only 1.7% of the total observed population variance.
Conclusion:
Most of the studied comorbidities and co-medications did not have a clinically important effect on statin response, suggesting no need to modify treatment regimens. However, use of metformin was associated with a significantly enhanced LDL-C response to statins, suggesting that lower statin doses may be effective in patients taking metformin.
More Related Videos
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Analysis of Population Pharmacokinetic Data
Lipids: Dietary Sources and Requirements
Factors Affecting Drug Response: Overview